MKRN1 Peptide
- Known as:
- MKRN1 Peptide
- Catalog number:
- 42-850P
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- Prosci
- Gene target:
- MKRN1 Peptide
Related genes to: MKRN1 Peptide
- Gene:
- MKRN1 NIH gene
- Name:
- makorin ring finger protein 1
- Previous symbol:
- -
- Synonyms:
- RNF61
- Chromosome:
- 7q34
- Locus Type:
- gene with protein product
- Date approved:
- 1999-10-19
- Date modifiied:
- 2014-11-19
Related products to: MKRN1 Peptide
Related articles to: MKRN1 Peptide
- Animal models of enhanced fertility are rare, as most genetically modified mouse models with reproductive phenotype display subfertility or infertility. Here we describe the ovarian phenotype of the Dummerstorf line 2 (FL2) mouse strain, which exhibits high fertility and has been selectively bred for increased fertility over more than 190 generations. This long-term selection, outbred mouse line almost doubled the litter size to 21.5 (FL2) compared to 11.3 (unselected control line, ctrl) without showing any signs of growth retardation in the offspring. Here we show that FL2 females ovulate 25.0 oocytes per cycle compared to 13.2 in ctrl. FL2 mice remain in the estrus phase for a shorter period during a 12-day observation period. Follicle-stimulating hormone (FSH) levels are decreased, both in estrus and diestrus, compared to ctrl, whereas Luteinizing hormone (LH) levels are unaffected. The mRNA expression levels in the pituitary gland correspond to the gonadotropin levels in the blood. Progesterone levels are decreased in estrus in FL2. Hypothalamic expression levels of Gonadotropin-releasing hormone (GnRH) are decreased in diestrus. Holistic gene expression analysis indicates complex and differential regulation in estrus and diestrus in ovaries of FL2 compared to ctrl. Especially genes of the TGF-β pathway (such as Bmp3, Bmp7, Inhba) and the Wnt pathway (such as Sfrp4, Mkrn1) are differentially expressed in ovaries of FL2 females. These data indicate that reduced activity of the hypothalamic-pituitary-gonadal axis (in particular, lower levels of GnRH, FSH and progesterone), combined with altered gene transcription in the ovaries, leads to higher ovulation rates in order to achieve the breeding objective of improved fertility. - Source: PubMed
Publication date: 2026/06/29
Ludwig Carolin L MBohleber SimonBaufeld AnjaWirth Eva KLanghammer MartinaSchweizer UlrichMichaelis MartenWeitzel Joachim M - Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms typically involving the upper gastrointestinal tract. Most GISTs are driven by activating mutations in the or genes, which are primary molecular markers for diagnosis and treatment. In addition, CD117 and DOG1 (discovered on GIST 1) are important immunohistochemical diagnostic markers of GISTs. Esophageal GISTs are exceptionally rare, and those driven by gene fusions are even more uncommon. This report describes a 69-year-old woman who underwent surgical resection of an esophageal GIST harboring an gene fusion, offering insight into future treatment and surveillance strategies. - Source: PubMed
Publication date: 2025/12/17
Kruithoff BradleyBeard LaurenLiebner DavidSatturwar SwatiLamb Matthew - Renal angiomyolipomas (AMLs) are clonal tumors formed by the abnormal differentiation of transformed renal progenitor cells. However, the cytogenetic and malignant transformations of renal AMLs require further investigation. Makorin ring finger protein 1 (MKRN1), a transcriptional co-regulator and E3 ubiquitin ligase, may act as a tumor regulator that mediates tumor biological processes. Although it is known as a prognostic marker of renal cell carcinoma, hepatocellular carcinoma, and pancreatic adenocarcinoma, its expression and function in renal AMLs remain unclear. Therefore, we aimed to investigate the expression and function of MKRN1 in AML cells. - Source: PubMed
Publication date: 2026/01/30
Chang Tzu-HsuanChang Ying-HsuLiu Chung-YiWang Tze-KaiPang Jacob See-TongChuang Cheng-Keng - An increased understanding of molecular alterations over the last decade has also impacted the landscape of sinonasal squamous cell carcinoma (SNSCC). In addition to traditional SCC risk factors (e.g. smoking) and high-risk HPV (HR- HPV), other drivers are emerging, such as DEK::AFF2 fusion in non-keratinizing and papillary SNSCC. Treatment of squamous cell carcinoma has been revolutionized with development of drugs that target key driver mutations and immune checkpoints. We describe a case report of nasal nonkeratinizing squamous cell carcinoma- HPV-high risk (HPV-HR) positive and harboring an MKRN1::BRAF fusion. We further discuss the significance of these findings, integrated in the context of current literature. - Source: PubMed
Publication date: 2026/03/13
Bell DianaWang Eric WChoby GarretSnyderman CarlArivarasan KarunamurthySeethala Raja R - BRAF, when mutated at V600E, is a well-known potent early oncogenic driver in papillary thyroid carcinoma (PTC), with potential prognostic and therapeutic implications. Non-V600E mutations are less common and without clear functional or therapeutic significance. One class of non-V600E mutations is BRAF gene fusions, which typically involve the C-terminal kinase domain of BRAF joined to a wide repertoire of potential N-terminal fusion partners. The aim of this study was to employ a sequential algorithmic approach to identify patients with BRAF fusions based on an integrated analysis of histologic, immunohistochemistry (IHC), and molecular (NGS) features of BRAF-rearranged PTCs. Nine patients with PTC previously scrutinized as BRAF V600E negative by IHC were analyzed by NGS. The studied 9 cases showed conventional PTC growth; 2 cases displayed a minor high-grade component (tall cell and hobnailing, < 20%), 1 case qualified as high-grade differentiated thyroid carcinoma (presence of necrosis and mitotic activity > 5 MF/ 2 mm; adjacent conventional PTC was present), and 1 case represented neck (lymph node) recurrence after 10 years. BRAF fusions were detected in all cases (10 different fusion partners: NRF1, MKRN1, MACF1, MTDH1, ARHGAP26, STRBF, FCHSDH2, POM121C, UBAP2L, SND1). To our knowledge, 7 of these fusions have not been reported so far in PTC (NRF1::BRAF, MTDH1::BRAF, ARHGAP26::BRAF, BRAF::STRBF, FCHSDH2::BRAF, BRAF::POM121C, UBAP2L::BRAF). In 3 PTCs, BRAF fusions were sole genomic events. Concurrent TERT (c.-124C > T) mutations were detected in 3 PTCs; pathogenic IGF2 amplification was present in another PTC, in addition to BRAF fusion. Two simultaneous fusions BRAF::STRBF and FCHSDH2::BRAF were found in one case of PTC; two BRAF fusions (BRAF::POM121C; UBAP2L::BRAF) co-existed with 2 FOXO1 fusions (FOXO1::TES, YWHAG::FOXO1) in one PTC. In summary, we report 7 new BRAF fusions in PTC BRAF V600E-WT. Additional clinical research is needed to elucidate the behavior of BRAF fusion-driven thyroid carcinomas and the therapeutic utility of MAPK pathway inhibitors. - Source: PubMed
Publication date: 2026/02/16
McGrath NathanLiang LiBakkar RaniaGernon Thomas JMaghami EllieAfkhami MichelleBell Diana